Relating to step therapy for metastatic cancer treatment.
Summary
HB 2536 would prohibit health benefit plans in Oregon from requiring step therapy before covering certain prescription drugs used to treat advanced metastatic cancer and related conditions. Step therapy is a utilization-management practice that requires a patient to try one or more lower-cost or preferred drugs before the insurer will cover the drug selected by the patient’s provider. Under this bill, if a covered drug is FDA-approved and its use is consistent with best practices and supported by peer-reviewed, evidence-based literature, the plan could not force a patient to fail first on other therapies before coverage begins.
The bill defines “advanced metastatic cancer” and “associated conditions” and adds the new protections to the Insurance Code. It applies to health benefit plans issued, offered, or renewed on or after January 1, 2026, and is exempt from a specified insurance statute, indicating the new rule would operate as a targeted exception within Oregon’s existing insurance coverage framework.
Impact
HB 2536 would amend Oregon insurance law by creating a specific prohibition on step therapy for advanced metastatic cancer treatment. It would affect health benefit plans regulated under the Insurance Code, limiting insurers’ ability to impose prior treatment sequencing requirements for qualifying prescription drugs used for metastatic cancer and related side effects or symptoms. The practical effect is to give oncologists and patients more direct access to certain FDA-approved therapies without insurer-mandated trial-and-fail requirements, beginning with plan years on or after January 1, 2026.
Sentiment
The available record shows no committee testimony or recorded votes, so there is no documented debate or formal legislative sentiment in the materials provided. Based on the bill’s subject matter and structure, the measure appears to be framed as a patient-access and cancer-treatment protection bill, with the apparent policy goal of reducing delays in care for people facing advanced metastatic cancer. Because no votes or hearing transcripts are included, support or opposition cannot be assessed from the record, though the bill’s narrow medical focus suggests it is likely intended as a targeted health coverage reform rather than a broad insurance overhaul.
Contention
The main policy tension inherent in the bill is between patient access to timely cancer treatment and insurers’ use of step therapy to control costs and encourage use of preferred drugs first. Supporters would likely emphasize that metastatic cancer patients should not be forced to try less effective or less appropriate therapies before receiving a provider-recommended drug, especially when the drug is FDA-approved and evidence-based. Potential critics, typically insurers or managed-care interests, may argue that the bill limits utilization management tools and could increase premiums or reduce flexibility in coverage design. No specific objections or amendments are documented in the provided materials.